GSK and CureVac to develop next generation mRNA COVID-19 vaccines
- Companies aim to develop a multi-valent candidate vaccine to address emerging variants for pandemic and endemic use
- Development to begin immediately targeting vaccine availability in 2022, subject to regulatory approval
- GSK will also support manufacture of up to 100 million doses of CureVac’s first generation COVID-19 vaccine CVnCoV in 2021
GlaxoSmithKline plc and CureVac N.V. today announced a new €150m collaboration, building on their existing relationship, to jointly develop next generation mRNA vaccines for COVID-19 with the potential for a multi-valent approach to address multiple emerging variants in one vaccine.